(Q45754408)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

review article

1 reference

title

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

author name string

C Trépo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

publication date

1 July 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

page(s)

151-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

Effect of interferon on hepatitis B.

2 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Combination therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Three recently described animal virus models for human hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Biochemical and genetic evidence for the hepatitis B virus replication strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The problem of antiviral therapy for chronic hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Evidence that less-than-full-length pol gene products are functional in hepadnavirus DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mutagenesis of a hepatitis B virus reverse transcriptase yields temperature-sensitive virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Novel mechanism for reverse transcription in hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The role of envelope proteins in hepatitis B virus assembly

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mapping a region of the large envelope protein required for hepatitis B virion maturation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Replicative intermediates of hepatitis B virus in HepG2 cells that produce infectious virions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

In vitro infection of woodchuck hepatocytes with woodchuck hepatitis virus and ground squirrel hepatitis virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Safety of famciclovir in patients with herpes zoster and genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatitis B reactivation after lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Famciclovir: review of clinical efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Clinical experience with famciclovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

The clinical significance of surface antigen variants of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translational initiation not ribosomal frameshifting

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Synthesis and encapsidation of duck hepatitis B virus reverse transcriptase do not require formation of core-polymerase fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Origin and evolution of retroelements based upon their reverse transcriptase sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

DNA vaccines and viral hepatitis: are we going around in circles?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Specific vaccine therapy in chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

Cleavage of hepatitis B virus RNA by three ribozymes transcribed from a single DNA template

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980191-8

7 January 2021

10.1016/S0168-8278(98)80191-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9696505%20AND%20SRC:MED&resulttype=core&format=json

2 December 2019

1 reference